Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
Citations Over TimeTop 10% of 2013 papers
Abstract
Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence. We isolated three TMZ-resistant human GBM cell lines and examined the expression of O6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR) components. We used immunohistochemical analysis to compare MutL homolog 1 (MLH1), postmeiotic segregation increased 2 (PMS2) and MGMT expression in primary and recurrent GBM specimens obtained from GBM patients during TMZ treatment. We found a reduction in MLH1 expression and a subsequent reduction in PMS2 protein levels in TMZ-resistant cells. Furthermore, MLH1 or PMS2 knockdown confered TMZ resistance. In recurrent GBM tumours, the expression of MLH1 and PMS2 was reduced when compared to primary tumours.
Related Papers
- → Mismatch repair genes in Lynch syndrome: a review(2009)78 cited
- → Microsatellite Instability and DNA Mismatch Repair Deficiency Testing in Hereditary and Sporadic Gastrointestinal Cancers(2005)59 cited
- → Phenotype associated with recessively inherited mutations in DNA mismatch repair (MMR) genes(2005)19 cited
- → Implication of expression of MMR proteins and clinicopathological characteristics in gastric cancer(2020)
- → Lynch Syndrome(2021)